The Epigenetic Features of CLL: DNA Methylation

Christoph Plass

German Cancer Research Center Heidelberg

c.plass@dkfz.de

iwCLL, 20-23 September 2019, Edinburgh-Scotland



GERMAN CANCER RESEARCH CENTER




Disclosures

• None

Epigenetic modifications

DNA Methylation




DNMT: DNA Methyltransferase


SAM: S-Adenosyl methionine, SAH: S-Adenosyl homocysteine

Epigenetic Modifications

Histone Modifications




Restriction Landmark Genomic Scanning (RLGS)




Results of a genome scan for DNA methylation in CLL

- over 3000 CpG islands were assayed in each sample.
- 2.5% to 8.1% (mean 4.8%) of the CpG islands in CLL samples were aberrantly methylated
- Patterns of methylation were non-random




Rush et al. Cancer Res. 64:2424-2433, 2004.


Cancer: Cell-of-origin and Epigenetics



Different developmental stages, aging and microenvironment:




Phylo(epi)genetic analysis of the development of blood cell types:




APE package in Bioconductor

The cellular origin of the CLL methylome




Isolation of B cells at various stages of maturation





Collaboration with Ralf Küppers and Marc Seifert

DNA methylation programming during B cell maturation




Progressive DNA methylation changes during B cell maturation





CLL patients form distinct clusters analogous to healthy B cell subtypes:




The degree of epigenetic programming normally achieved during affinity maturation defines CLL subgroups:


- LP-CLL (<u>L</u>ess <u>P</u>rogrammed)
- IP-CLL (<u>Intermediate Programmed</u>)
- HP-CLL (<u>Highly Programmed</u>)

- ≈ IGHV Unmutated
- ≈ IGHV Mutated

Using DNA methylation to estimate the cellular origin of the B cell in which the block of differentiation occurred:




ZAP70 promoter methylation in CLL



Claus et al. J Clin Oncol. 2012

ZAP70 promoter methylation in CLL

 DNA methylation at a single CpG dinucleotide in the ZAP-70 promoter region impacts on ZAP-70 transcriptional regulation and is prognostic in CLL




Claus et al. J Clin Oncol. 2012

Discriminating CLL-specific epigenetic alterations from developmental epigentic alterations

Problem: discrimination between sites that are epigenetically remodeled during B cell differentiation and sites that are modified during leukemogenesis.


Solution: Modelling the epigenome of the cellular origin for CLLs






Wierzbinska JA et al. unpublished

Dissecting CLL-specific epigenetic alterations




Sites with epigenetic B-cell programming



CLL-specific reprogramming

Sites with epigenetic B-cell programming



-100

∆Meth [%]

-100

-100

NBCs hiMBCs

50

60

DS [%]

70

DS [%]

70


60

-100

50


NBCs hiMBCs

Proportion of disease-specific events




- **Hypomethylation** accounts for majority of disease-specific methylation events
- The vast proportion of CLL-specific methylation occurs on CpG sites not affected during B-cell programming
- CLL-specific methylation events are rare

Differential methylation: CD19+ B vers. cell of origin




More than 10-fold overestimation of epigenetic contribution to gene silencing using CD19+ controls

Disease-specific epigenetic alterations in regulatory sequences for miRNAs









DS [%]

Target genes enriched for epigenetic enzymes




Epigenetically deregulated transcripts show aberrant protein expression in CLL




Activated genes:

lymphocyte/T-lymphocyte related processes



nMFI



Conclusions

- Normal B cells undergo massive epigenetic reprogramming during the germinal center reaction
- Linear regression modeling allows to compute the methylome of the cell-of-origin for each CLL
- Previous DNA methylation analysis overestimated the number of epigenetically silenced genes in CLL

Acknowledgments:

DKFZ Heidelberg

- **Division of Epigenomics and Cancer Risk Factors**
- **Christoph Plass**
- Christopher Oakes (now The Ohio State University)
- Justyna Wierzbinska
- Daniel Lipka
- Reka Toth
- Dieter Weichenhan
- **Molecular Genetics**
- Martina Seifert / Philipp Rößner
- **NCT Heidelberg**
- Molecular Therapy in Hematology and Oncology
- Thorsten Zenz
- **Bioquant**
- **Genome Organization and Function**
- Karsten Rippe
- **Daniel Mertens**
- **Precise Consortium**





GERMAN CANCER RESEARCH CENTER Essen: Ralf Küppers Essen: Marc Seifert Augsburg: Rainer Claus

